Evidence map›Paper›PMID 41490989›Full record

ArticleBiomolecules & therapeutics2026

Preclinical Pharmacological and Toxicological Evaluation of SB5794, a Novel Aryl Hydrocarbon Receptor Modulator on the Kynurenine-AhR Axis.

Daewon Cha, Soo-Jung Choi, Hyunwoo Park, Dae Young Lee, Min Sung Joo, Wonhyung Lee, Jungsang Park, Eunhye Lee, Hakwon Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daewon ChaDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Soo-Jung ChoiDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Hyunwoo ParkDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Dae Young LeeDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Min Sung JooDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Wonhyung LeeDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Jungsang ParkDong-A ST Research Institute, Yongin 17073, Republic of Korea.
Eunhye LeeNew Drug Discovery Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
Hakwon KimDepartment of Applied Chemistry and Global Center for Pharmaceutical Ingredient, Kyung Hee University, Yongin 17104, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional aryl hydrocarbon receptor (AhR) antagonists, which play a critical role in modulating tumor immune evasion, have shown limited clinical translation due to poor solubility, restricted systemic exposure, and dose-limiting toxicities. To overcome these limitations, we developed SB5794, a phosphate prodrug of the potent AhR antagonist SB2617, designed to improve aqueous solubility and pharmacokinetic properties. SB5794 exhibited markedly enhanced solubility and achieved more than six-fold higher systemic exposure in mice compared with SB2617, while fully retaining its

Indexed as

Antitumor activityAryl hydrocarbon receptor (AhR) antagonistImmunomodulatory activityKynurenine–AhR signalingPhosphate prodrug (SB5794)

Identifiers

PMID41490989
PMCPMC12782866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.